Cargando…

Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells

Previous vaccination studies in patients with castration-resistant prostate cancer (CRPC) showed improved survival without prolongation of progression-free survival (PFS). This might be explained by enhanced efficacy of subsequent therapies because of heightened immune status. We therefore evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Dodewaard-de Jong, Joyce M., Santegoets, Saskia JAM, van de Ven, Peter M., Versluis, Jurjen, Verheul, Henk M. W., de Gruijl, Tanja D., Gerritsen, Winald R., van den Eertwegh, Alfons J. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839338/ https://www.ncbi.nlm.nih.gov/pubmed/27141390 http://dx.doi.org/10.1080/2162402X.2015.1105431

Ejemplares similares

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab
por: Santegoets, Saskia JAM, et al.
Publicado: (2014)

S48. Biomarker development for ipilimumab and prostate GVAX treatment
por: de Gruijl, T, et al.
Publicado: (2014)

Current and Emerging Treatment Options for Castration-Resistant Prostate Cancer: A Focus on Immunotherapy
por: Gerritsen, Winald R., et al.
Publicado: (2011)

IL-21 promotes the expansion of CD27(+)CD28(+) tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells
por: Santegoets, Saskia JAM, et al.
Publicado: (2013)

Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node
por: van den Hout, Mari F. C. M., et al.
Publicado: (2016)

Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
por: Huijts, Charlotte M, et al.
Publicado: (2011)

Dual-Phase PET-CT to Differentiate [(18)F]Fluoromethylcholine Uptake in Reactive and Malignant Lymph Nodes in Patients with Prostate Cancer
por: Oprea-Lager, Daniela E., et al.
Publicado: (2012)

Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer
por: Holleman, Marscha S., et al.
Publicado: (2022)

Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223
por: van der Doelen, Maarten J., et al.
Publicado: (2021)

Functional characterization of a STAT3-dependent dendritic cell-derived CD14(+) cell population arising upon IL-10-driven maturation
por: Lindenberg, Jelle J., et al.
Publicado: (2013)

Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide
por: Benoist, Guillemette E., et al.
Publicado: (2016)

High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer
por: Westdorp, Harm, et al.
Publicado: (2020)

Pre-operative intradermal administration of CpG-B ± GM-CSF in stage I-III melanoma patients arms the sentinel lymph node: evidence for reduced tumor spread
por: van den Hout, Mari F, et al.
Publicado: (2013)

Sensitivity of (18)F-fluorodihydrotestosterone PET-CT to count statistics and reconstruction protocol in metastatic castration-resistant prostate cancer
por: Cysouw, Matthijs C. F., et al.
Publicado: (2019)

A clinician’s guide for developing a prediction model: a case study using real-world data of patients with castration-resistant prostate cancer
por: Veen, Kevin M., et al.
Publicado: (2020)

Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy
por: van der Doelen, Maarten J., et al.
Publicado: (2022)

In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma
por: Koster, Bas D., et al.
Publicado: (2019)

Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial
por: Koster, Bas D., et al.
Publicado: (2019)

Impact of DNA damage repair defects and aggressive variant features on response to carboplatin‐based chemotherapy in metastatic castration‐resistant prostate cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2020)

Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines
por: de Gruijl, Tanja D., et al.
Publicado: (2008)

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
por: Westdorp, Harm, et al.
Publicado: (2019)

Priming of PRAME- and WT1-specific CD8(+) T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapy
por: van den Ancker, Willemijn, et al.
Publicado: (2013)

Immunological effects of everolimus in patients with metastatic renal cell cancer
por: Huijts, Charlotte M, et al.
Publicado: (2017)

Castration for Prostatic Hypertrophy
Publicado: (1899)

Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer
por: van Cruijsen, Hester, et al.
Publicado: (2009)

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
por: Gulley, James L., et al.
Publicado: (2019)

A Compendium of AR Splice Variants in Metastatic Castration-Resistant Prostate Cancer
por: Isebia, Khrystany T., et al.
Publicado: (2023)

Adjuvant treatment of early-stage melanoma by local i.d. administration of low-dose CpG-B and GM-CSF increases recurrence-free survival: long-term follow-up of three randomized clinical trials
por: de Gruijl, Tanja D, et al.
Publicado: (2015)

Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition
por: Oosterhoff, Dinja, et al.
Publicado: (2012)

Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer
por: Mout, Lisanne, et al.
Publicado: (2020)

Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2017)

Transcriptome analysis of differentially expressed genes and pathways associated with mitoxantrone treatment prostate cancer
por: Li, Sanqiang, et al.
Publicado: (2018)

Reappraisal of glucocorticoids in castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel
por: Belderbos, Bodine P.S., et al.
Publicado: (2017)

Castration for Hypertrophy of the Prostate Gland
Publicado: (1895)

Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2018)

11-Ketotestosterone is the predominant active androgen in prostate cancer patients after castration
por: Snaterse, Gido, et al.
Publicado: (2021)

RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Boerrigter, Emmy, et al.
Publicado: (2021)

IL-10 Conditioning of Human Skin Affects the Distribution of Migratory Dendritic Cell Subsets and Functional T Cell Differentiation
por: Lindenberg, Jelle J., et al.
Publicado: (2013)

A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer
por: Collins, R, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_h2s2as82rotnmguqijejr33fhb